CS
RNAC icon

Candriam SCA’s Cartesian Therapeutics RNAC Stock Holding History

Candriam SCA’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-4,767
Closed -$2.22M – 843
2018
Q3 		$2.22M Hold
4,767
– – 0.03% 481
2018
Q2 		$1.9M Hold
4,767
– – 0.03% 498
2018
Q1 		$1.46M Hold
4,767
– – 0.02% 533
2017
Q4 		$1.4M Hold
4,767
– – 0.02% 521
2017
Q3 		$2.61M Buy
4,767
+567
+14% +$302K 0.05% 400
2017
Q2 		$2.5M Buy
4,200
+3,167
+307% +$1.4M 0.05% 419
2017
Q1 		$444K Buy
+1,033
New +$435K 0.01% 652

Other funds holding RNAC

PVMCV
Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Man Group
Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return
SRF
Silver Rock Financial Los Angeles, California $49.7M AUM 17.42% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Candriam SCA's RNAC Position: Q4 2018 in Review

Candriam SCA sold out of Cartesian Therapeutics (RNAC) in Q4 2018, closing a stake of 4,767 shares — an estimated $2.22M sold.

Candriam SCA first reported a position in RNAC in Q1 2017 and held it in 7 quarters. The position peaked at $2.61M in Q3 2017. 54 funds tracked by Wall St. Rank hold RNAC as of Q4 2018.

  • Candriam SCA reported no remaining Cartesian Therapeutics position as of Q4 2018 after selling out during the quarter.
  • Candriam SCA sold 4,767 Cartesian Therapeutics shares in Q4 2018, an estimated $2.22M.
  • Candriam SCA first reported a position in Cartesian Therapeutics in Q1 2017 and held it in 7 quarters.
  • Candriam SCA's Cartesian Therapeutics position peaked at $2.61M in Q3 2017.
  • 54 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q4 2018.

Based on Candriam SCA's 13F filing for Q4 2018, filed 14 Feb 2019.